RxDoctor Payments Data

Randall Mercier, MD

Internal Medicine · Southern Pines, NCNPI 1780878116

Payments from drug & device makers

$7,115in general payments, 2019–2025

Across 456 payments — averaging $15.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$899
  • AbbVie$845
  • Amgen$472
  • Boehringer Ingelheim$387
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$7,06699%
  • Education$491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,115 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$234,456
Medicare patients
338
Services billed
5,345

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin196$230,966
EliquisApixaban131$123,435
MounjaroTirzepatide98$116,547
OzempicSemaglutide87$102,409
ProliaDenosumab45$76,836
FarxigaDapagliflozin Propanediol74$66,446
OtezlaApremilast11$51,584
JanuviaSitagliptin Phosphate20$30,335
LinzessLinaclotide39$26,972
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$25,131
XareltoRivaroxaban17$24,910
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$19,837
TrulicityDulaglutide17$19,397
EdarbiAzilsartan Medoxomil29$18,307
TrintellixVortioxetine Hydrobromide30$15,516

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$387$230,966196 claims
Lilly USA, LLCMounjaro, Trulicity$1,014$135,945115 claims
AmgenProlia, Otezla$472$128,42056 claims
PfizerEliquis, Paxlovid$141$127,616166 claims
Novo NordiskOzempic$899$102,40987 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,062$86,28396 claims
AbbVieLinzess, Synthroid$845$33,906113 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$182$33,37943 claims
MerckJanuvia$84$30,33520 claims
Johnson & JohnsonXarelto$58$24,91017 claims
Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor$189$24,13240 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$183$23,47443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Southern Pines

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →